Manufacturing Partnerships VET platform and a recent LOI with Matica Biotech suggest KaliVir is well positioned to pursue contract development and manufacturing partnerships, offering GMP-ready viral vector production, process development, and tech transfer to scale multi-transgene oncolytic therapies.

Academic Collaborations Strong ties to the University of Pittsburgh and ongoing participation in major conferences indicate openness to sponsored research, licensing discussions, and collaborative programs that can accelerate translational development of the platform.

Platform Licensing Vaccinia Enhanced Template enables expression and systemic delivery of multiple therapeutic transgenes, creating opportunities to license or co-develop the platform with pharma players seeking multi-target immunotherapies in oncology.

Clinical Readiness Leadership additions such as a Chief Medical Officer and a viral immunotherapy expert on the board, combined with preclinical data demonstrations, point to a trajectory toward clinical development and services like CRO, regulatory strategy, and trial design support.

Strategic Partnerships With an established revenue base and a focused pipeline, KaliVir appears attractive for strategic investments, co-development partnerships, or licensing deals to monetize its platform and accelerate program timelines.